PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Paclitaxel is a drug of choice and has been approved for the treatment of ovarian cancer [PMID: 9735871, PMID: 9891802].
Approved for metastatic breast cancer and adjuvant treatment of node-positive breast cancer; it has shown single agent activity in excess of 50% [PMID: 19803922, PMID: 7908664].
Used in the therapy of lung cancers, including activity in non-small cell lung cancer [PMID: 31644104, PMID: 1980498].
Activity has been reported against esophageal, prostate, bladder, head and neck, testicular, and endometrial tumors [PMID: 31644104, PMID: 12125509].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 31644104 (2012) — Paclitaxel-induced neuropathy. · Annals of oncology : official journal of the European Society for Medical Oncology
- 2.PMID: 12125509 (2002) — Taxol reactions. · Allergy and asthma proceedings
- 3.PMID: 9000007 (1996) — Fluorescent taxoids. · Chemistry & biology
- 4.PMID: 1453701 (1992) — The pharmacology of extinction. · Journal of ethnopharmacology
- 5.PMID: 34261255 (1995) — Ecology of Pacific Yew (Taxus brevifolia) in Western Oregon and Washington. · Conservation biology : the journal of the Society for Conservation Biology